Acumen eCTD Templates

Acumen Template Library

Browse the full template suite or the templates included in the IND suite.

453Full Suite templates
179IND Suite templates
12Template categories
SubfolderFilenameType
Acumen Generic Style GuideGeneric Style Guide Acumen template.docxDOCX
ANDA1.12.10 Generic Drug Enforcement Act Statement_ANDA.docxDOCX
ANDA1.12.11 Basis for Submission_ANDA.docxDOCX
ANDA1.12.12 Comparison Between Generic Drug and Reference Listed Drug_ANDA.docxDOCX
ANDA1.12.14 Environmental Assessment_ANDA.docxDOCX
ANDA1.12.15 Request for Waiver of In Vivo Bioavailability Studies_ANDA.docxDOCX
ANDA1.14.1.2 Annotated Draft Labeling Text_ANDA.docxDOCX
ANDA1.14.3.1 Annotated Comparison with Listed Drug_ANDA.docxDOCX
ANDA1.3.3 Debarment Certification_ANDA.docxDOCX
ANDA1.3.5.2 Patent Certification_ANDA.docxDOCX
ANDA2.3 Introduction to Quality Overall Summary_ANDA.docxDOCX
ANDA2.3 Quality Overall Summary_ANDA.docxDOCX
ANDA2.3.P.1 Description and Composition of the Drug Product_ANDA.docxDOCX
ANDA2.3.P.2 Pharmaceutical Development_ANDA.docxDOCX
ANDA2.3.P.3 Manufacture_ANDA.docxDOCX
ANDA2.3.P.4 Control of Excipients_ANDA.docxDOCX
ANDA2.3.P.5 Control of Drug Product_ANDA.docxDOCX
ANDA2.3.P.6 Reference Standards or Materials_ANDA.docxDOCX
ANDA2.3.P.7 Container Closure System_ANDA.docxDOCX
ANDA2.3.P.8 Stability_ANDA.docxDOCX
ANDA2.3.S.1 General Information_ANDA.docxDOCX
ANDA2.3.S.2 Manufacture_ANDA.docxDOCX
ANDA2.3.S.3 Characterization_ANDA.docxDOCX
ANDA2.3.S.4 Control of Drug Substance_ANDA.docxDOCX
ANDA2.3.S.5 Reference Standards or Materials_ANDA.docxDOCX
ANDA2.3.S.6 Container Closure System_ANDA.docxDOCX
ANDA2.3.S.7 Stability_ANDA.docxDOCX
ANDA2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods_ANDA.docxDOCX
ANDABioequivalence Summary Data Tables_ANDA.docxDOCX
Module 1 EMA1.0 EU Cover Letter.docxDOCX
Module 1 EMA1.3 EU Product Information.docxDOCX
Module 1 EMA1.3.1 EU SmPC, Labelling, and Package Leaflet.docxDOCX
Module 1 EMA1.3.4 EU Consultation with Target Patient Groups.docxDOCX
Module 1 EMA1.4.1 EU Information About the Experts Quality.docxDOCX
Module 1 EMA1.4.2 EU Information About the Experts NonClinical.docxDOCX
Module 1 EMA1.4.3 EU Information About the Experts Clinical.docxDOCX
Module 1 EMA1.5.1 EU Information for Bibliographical Applications.docxDOCX
Module 1 EMA1.5.2 EU Information for Generic Hybrid Bio-similar Applications.docxDOCX
Module 1 EMA1.5.3 EU Extended Data Market Exclusivity.docxDOCX
Module 1 EMA1.5.4 EU Exceptional Circumstance.docxDOCX
Module 1 EMA1.5.5 EU Conditional Marketing Authorisation.docxDOCX
Module 1 EMA1.6 EU Environmental Risk Assessment.docxDOCX
Module 1 EMA1.7.1 EU Information Relating to Orphan Market Exclusivity Similarity.docxDOCX
Module 1 EMA1.7.2 EU Information Relating to Orphan Market Exclusivity.docxDOCX
Module 1 EMA1.8.1 EU Pharmacovigilance System.docxDOCX
Module 1 EMA1.8.2 EU Risk Management Plan.docxDOCX
Module 1 EMA1.9 EU Information Relating to Clinical Trials.docxDOCX
Module 1 EMAIMPD full template.docxDOCX
Module 1 FDA1.10.1 Request for Dispute Resolution.docxDOCX
Module 1 FDA1.10.2 Correspondence Related to Dispute Resolution.docxDOCX
Module 1 FDA1.11.1 Quality Information Amendment.docxDOCX
Module 1 FDA1.11.2 Nonclinical Information Amendment.docxDOCX
Module 1 FDA1.11.3 Clinical Information Amendment.docxDOCX
Module 1 FDA1.11.4 Multiple Module Information Amendment.docxDOCX
Module 1 FDA1.12.1 Pre-IND Correspondence.docxDOCX
Module 1 FDA1.12.13 Request for Waiver for In Vivo Studies.docxDOCX
Module 1 FDA1.12.14 Environmental Assessment - Categorical Exclusion.docxDOCX
Module 1 FDA1.12.14 Environmental Assessment.docxDOCX
Module 1 FDA1.12.15 Request for Waiver for In Vivo Bioavailability Studies.docxDOCX
Module 1 FDA1.12.16 Field Alert Reports.docxDOCX
Module 1 FDA1.12.17 Orphan Drug Designation.docxDOCX
Module 1 FDA1.12.2 Request to Charge for Clinical Trial.docxDOCX
Module 1 FDA1.12.3 Request to Charge for Expanded Access.docxDOCX
Module 1 FDA1.12.4 Request for Comment_Advice.docxDOCX
Module 1 FDA1.12.5 Request for a Waiver.docxDOCX
Module 1 FDA1.12.6 Exemption from Informed Consent for Emergency Research.docxDOCX
Module 1 FDA1.12.7 Public Disclosure Statement for Exemption from Informed Consent for Emergency Research.docxDOCX
Module 1 FDA1.12.8 Correspondence Regarding Exemption from Informed Consent for Emergency Research.docxDOCX
Module 1 FDA1.12.9 Notification of Discontinuation of Clinical Trial.docxDOCX
Module 1 FDA1.13.1 Summary for Nonclinical Studies - IND Annual Report.docxDOCX
Module 1 FDA1.13.1 Summary for Nonclinical Studies - NDA Annual Report.docxDOCX
Module 1 FDA1.13.10 Foreign Marketing.docxDOCX
Module 1 FDA1.13.11 Distribution Data.docxDOCX
Module 1 FDA1.13.12 Status of Postmarketing Study Commitments and Requirements .docxDOCX
Module 1 FDA1.13.13 Status of Other Postmarketing Studies and Requirements.docxDOCX
Module 1 FDA1.13.14 Log of Outstanding Regulatory Business - IND Annual Report.docxDOCX
Module 1 FDA1.13.14 Log of Outstanding Regulatory Business - NDA Annual Report.docxDOCX
Module 1 FDA1.13.15 Development Safety Update Report (DSUR).docxDOCX
Module 1 FDA1.13.2 Summary for Clinical Pharmacology Information - IND Annual Report.docxDOCX
Module 1 FDA1.13.2 Summary for Clinical Pharmacology Information - NDA Annual Report.docxDOCX
Module 1 FDA1.13.3 Summary of Safety Information - IND Annual Report.docxDOCX
Module 1 FDA1.13.3 Summary of Safety Information - NDA Annual Report.docxDOCX
Module 1 FDA1.13.4 Summary of Labeling Changes.docxDOCX
Module 1 FDA1.13.5 Summary of Manufacturing Changes - IND Annual Report.docxDOCX
Module 1 FDA1.13.5 Summary of Manufacturing Changes - NDA Annual Report.docxDOCX
Module 1 FDA1.13.6 Summary of Microbiological Changes.docxDOCX
Module 1 FDA1.13.7 Summary of Other Significant New Information.docxDOCX
Module 1 FDA1.13.8 Individual Study Information.docxDOCX
Module 1 FDA1.13.9 General Investigational Plan.docxDOCX
Module 1 FDA1.14.1 Draft Labeling.docxDOCX
Module 1 FDA1.14.1.2 Annotated Draft Labeling Text.docxDOCX
Module 1 FDA1.14.1.3 Draft Labeling Text.docxDOCX
Module 1 FDA1.14.1.4 Labeling Comprehension Studies.docxDOCX
Module 1 FDA1.14.1.5 Labeling History.docxDOCX
Module 1 FDA1.14.2.1 Final Carton and Container Labels.docxDOCX
Module 1 FDA1.14.2.2 Final Package Insert_Placeholder.docxDOCX
Module 1 FDA1.14.2.3 Final Labeling Text.docxDOCX
Module 1 FDA1.14.3.1 Annotated Comparison with Reference Listed Drug (RLD).docxDOCX
Module 1 FDA1.14.3.2 Approved Labeling Text for Reference Listed Drug (RLD).docxDOCX
Module 1 FDA1.14.3.3 Labeling Text for Reference Listed Drug (RLD).docxDOCX
Module 1 FDA1.14.4.1 Investigator's Brochure.docxDOCX
Module 1 FDA1.14.4.2 Investigational Drug Labeling.docxDOCX
Module 1 FDA1.14.5 Foreign Labeling.docxDOCX
Module 1 FDA1.14.6 Product Labeling for 2253 Submissions.docxDOCX
Module 1 FDA1.15 General Considerations.docxDOCX
Module 1 FDA1.15 Presentation Issues.docxDOCX
Module 1 FDA1.15 Promotional Complaints.docxDOCX
Module 1 FDA1.15 Promotional Format for Electronic Submission.docxDOCX
Module 1 FDA1.15 Promotional Material Submitted in Fulfillment of the Postmarketing Reporting Requirements.docxDOCX
Module 1 FDA1.15 Promotional Materials Paper Hard Copy.docxDOCX
Module 1 FDA1.15.1.1 Request for Advisory Comments on Launch Materials .docxDOCX
Module 1 FDA1.15.1.10 Submission of Annotated References.docxDOCX
Module 1 FDA1.15.1.11 General Correspondence.docxDOCX
Module 1 FDA1.15.1.2 Request for Advisory Comments on Non-Launch Materials.docxDOCX
Module 1 FDA1.15.1.3 Presubmission of Launch Promotional Materials for Accelerated Approval Products.docxDOCX
Module 1 FDA1.15.1.4 Presubmission of Non-Launch Promotional Materials for Accelerated Approval Products.docxDOCX
Module 1 FDA1.15.1.5 Pre-dissemination Review of Television Ads.docxDOCX
Module 1 FDA1.15.1.6 Response to Untitled Letter or Warning Letter.docxDOCX
Module 1 FDA1.15.1.7 Response to Information Request.docxDOCX
Module 1 FDA1.15.1.8 Correspondence Accompanying Materials Previously Missing or Rejected.docxDOCX
Module 1 FDA1.15.1.9 Withdrawal Request.docxDOCX
Module 1 FDA1.16 Proposed Risk Evaluation and Mitigation Strategies (REMS) With Supporting Document.docxDOCX
Module 1 FDA1.16 Proposed Risk Evaluation and Mitigation Strategies (REMS) Without Supporting Documentation.docxDOCX
Module 1 FDA1.16 Proposed Risk Evaluation and Mitigation Strategies (REMS).docxDOCX
Module 1 FDA1.16 Risk Management Plans.docxDOCX
Module 1 FDA1.16.2.1 Final REMS_Placeholder.docxDOCX
Module 1 FDA1.16.2.2 Draft REMS_Placeholder.docxDOCX
Module 1 FDA1.16.2.3 Risk Evaluation and Mitigation Strategies (REMS) Assessment.docxDOCX
Module 1 FDA1.16.2.4 Risk Evaluation and Mitigation Strategies (REMS) Assessment Methodology.docxDOCX
Module 1 FDA1.16.2.5 Risk Evlauation and Mitigation Strategies (REMS) Assessment Correspondence.docxDOCX
Module 1 FDA1.16.2.6 Risk Evlauation and Mitigation Strategies (REMS) Modification History.docxDOCX
Module 1 FDA1.17.1 Correspondence Regarding Postmarketing Commitments.docxDOCX
Module 1 FDA1.17.2 Correspondence Regarding Postmarketing Requirements.docxDOCX
Module 1 FDA1.19 Emergency Use Authorization Request.docxDOCX
Module 1 FDA1.2 Cover Letter - Initial IND Application.docxDOCX
Module 1 FDA1.2 Cover Letter - Original NDA Application.docxDOCX
Module 1 FDA1.2 Reviewer's Guide.docxDOCX
Module 1 FDA1.20 General Investigational Plan for Initial IND.docxDOCX
Module 1 FDA1.3.1.1 Change of Address.docxDOCX
Module 1 FDA1.3.1.2 Change of Contact Agent.docxDOCX
Module 1 FDA1.3.1.3 Change of Sponsor.docxDOCX
Module 1 FDA1.3.1.4 Transfer of Regulatory Obligation.docxDOCX
Module 1 FDA1.3.1.5 Change in Ownership of an Application or Reissuance of License .docxDOCX
Module 1 FDA1.3.2 Field Copy Certification.docxDOCX
Module 1 FDA1.3.3 Debarment Certification.docxDOCX
Module 1 FDA1.3.4 Financial Certification and Disclosure.docxDOCX
Module 1 FDA1.3.5.1 Patent Information_Placeholder.docxDOCX
Module 1 FDA1.3.5.2 Patent Certifications.docxDOCX
Module 1 FDA1.3.5.3 Exclusivity Claim.docxDOCX
Module 1 FDA1.3.6 Tropical Disease Piority Review Voucher.docxDOCX
Module 1 FDA1.4.1 Letter of Authorization_Placeholder.docxDOCX
Module 1 FDA1.4.2 Statement of Right of Reference_Placeholder.docxDOCX
Module 1 FDA1.4.4 Cross-reference to Previously Submitted Information.docxDOCX
Module 1 FDA1.5.1 Withdrawal of IND.docxDOCX
Module 1 FDA1.5.2 Inactivation Request.docxDOCX
Module 1 FDA1.5.3 Reactivation Request.docxDOCX
Module 1 FDA1.5.4 Reinstatement Request.docxDOCX
Module 1 FDA1.5.5 Withdrawal of an Unapproved Application.docxDOCX
Module 1 FDA1.5.6 Withdrawal of a Listed Drug.docxDOCX
Module 1 FDA1.5.7 Withdrawal of approval of an application or revocation of license.docxDOCX
Module 1 FDA1.6.1 Meeting Request.docxDOCX
Module 1 FDA1.6.1 Meeting Request_Biosimilar_Biologics.docxDOCX
Module 1 FDA1.6.2 Pre-IND Meeting Background Materials.docxDOCX
Module 1 FDA1.6.2 Pre-NDA Meeting Background Materials.docxDOCX
Module 1 FDA1.6.3 Correspondence Regarding Meetings-1.docxDOCX
Module 1 FDA1.7.1 Fast Track Designation.docxDOCX
Module 1 FDA1.7.2 Fast Track Designation Withdrawal Request.docxDOCX
Module 1 FDA1.7.3 Rolling Review Request.docxDOCX
Module 1 FDA1.8.1 Special Protocol Assessment Request_Clinical Study.docxDOCX
Module 1 FDA1.8.2 Special Protocol Assessment_Carcinogenicity Study.docxDOCX
Module 1 FDA1.8.3 Special Protocol Assessment Request_Stability Study.docxDOCX
Module 1 FDA1.9.1 Request for Waiver of Pediatric Studies.docxDOCX
Module 1 FDA1.9.2 Request for Deferral of Pediatric Studies.docxDOCX
Module 1 FDA1.9.4 Pediatric Study Plan.docxDOCX
Module 1 FDA1.9.6 Other Correspondence Regarding Pediatric Exclusivity or Study Plans.docxDOCX
Module 1 FDABreakthrough Therapy Designation.docxDOCX
Module 1 FDAClinical Data - NDA Annual Report_Placeholder.docxDOCX
Module 1 FDACMC - NDA Annual Report_Placeholder.docxDOCX
Module 1 FDACore Data Sheet - 1.docxDOCX
Module 1 FDAIB Update Summary of Changes.docxDOCX
Module 1 FDAInvestigator's Brochure Addendum (1.14.4.1).docxDOCX
Module 1 FDANonclinical Studies - NDA Annual Report_Placeholder.docxDOCX
Module 1 FDAPaper IND to eCTD Conversion_Cover Letter.docxDOCX
Module 1 FDAPhase I Protocol Modifications - IND Annual Report_Placeholder.docxDOCX
Module 1 FDAPhysician's Labeling Rule_Content.docxDOCX
Module 1 FDARequest for Proprietary Name Review.docxDOCX
Module 1 FDATarget Product Profile.docxDOCX
Module 1 FDATop-Line Data Template.docxDOCX
Module 1 Health Canada1.0.1 CA Cover Letter.docxDOCX
Module 1 Health Canada1.0.3 Copy of Health Canada issued correspondence.docxDOCX
Module 1 Health Canada1.0.4 CA Health Canada Solicited Information.docxDOCX
Module 1 Health Canada1.0.5 Meeting Information.docxDOCX
Module 1 Health Canada1.0.6 Request for Reconsideration Document.docxDOCX
Module 1 Health Canada1.0.7 CA General Note to Reviewer.docxDOCX
Module 1 Health Canada1.2.3 Certification and Attestation Forms.docxDOCX
Module 1 Health Canada1.2.4.1 Patent Information.docxDOCX
Module 1 Health Canada1.2.4.2 CA Data Protection Information.docxDOCX
Module 1 Health Canada1.2.5.1 Clinical Trial Site Information Form.docxDOCX
Module 1 Health Canada1.2.5.2 Establishment Licensing.docxDOCX
Module 1 Health Canada1.2.5.3 Good Clinical Practices.docxDOCX
Module 1 Health Canada1.2.5.4 Good Laboratory Practices.docxDOCX
Module 1 Health Canada1.2.5.5 Good Manufacturing Practices.docxDOCX
Module 1 Health Canada1.2.5.6 Good Pharmacovigilance Practices.docxDOCX
Module 1 Health Canada1.2.5.7 Other Compliance and Site Information.docxDOCX
Module 1 Health Canada1.2.6 Authorization for Sharing Information.docxDOCX
Module 1 Health Canada1.2.7 International Information.docxDOCX
Module 1 Health Canada1.2.8 Post-Authorization Information.docxDOCX
Module 1 Health Canada1.2.9 Other Administrative Information.docxDOCX
Module 1 Health Canada1.3.1 CA Product Monograph.docxDOCX
Module 1 Health Canada1.3.2 Inner and Outer Labels.docxDOCX
Module 1 Health Canada1.3.3 Non-Canadian Labelling.docxDOCX
Module 1 Health Canada1.3.4 CA Investigator Brochure.docxDOCX
Module 1 Health Canada1.3.5 Reference Product Labelling.docxDOCX
Module 1 Health Canada1.3.6 Certified Product Information Document.docxDOCX
Module 1 Health Canada1.3.7 CA Look-alike Sound-alike Assessment.docxDOCX
Module 1 Health Canada1.3.8.1 Pharmacovigilance Plan.docxDOCX
Module 1 Health Canada1.3.8.2 CA Risk Management Plan.docxDOCX
Module 1 Health Canada1.3.8.3 Risk Communications.docxDOCX
Module 1 Health Canada1.3.8.4 Other Pharmacovigilance Information.docxDOCX
Module 1 Health Canada1.4.1 CA PSEAT-CTA.docxDOCX
Module 1 Health Canada1.4.2 Comprehensive Summary Bioequivalence.docxDOCX
Module 1 Health Canada1.4.3 Multidisciplinary Tabular Summaries.docxDOCX
Module 1 Health Canada1.5 CA Environmental Assessment Statement.docxDOCX
Module 1 Health Canada1.6 Regional Clinical Information.docxDOCX
Module 1 Health Canada1.7 Clinical Trial Information.docxDOCX
Module 1 MHRA1.0 MHRA Cover Letter and 1.2 Electronic Application Form.docxDOCX
Module 1 MHRA1.3.1 Intermediate Packaging.docxDOCX
Module 1 MHRA1.3.1 Package Leaflet.docxDOCX
Module 1 MHRA1.3.1 SmPC, Labelling, and Package Leaflet.docxDOCX
Module 1 MHRA1.3.1 Summary of Product Characteristics.docxDOCX
Module 1 MHRA1.3.4 Consultation with Target Patient Groups.docxDOCX
Module 1 MHRA1.3.6 Braille.docxDOCX
Module 1 MHRA1.4.1 Information About the Experts Quality.docxDOCX
Module 1 MHRA1.4.2 Information About the Experts NonClinical.docxDOCX
Module 1 MHRA1.4.3 Information About the Experts Clinical.docxDOCX
Module 1 MHRA1.5 Specific Requirements for Different Types of Applications.docxDOCX
Module 1 MHRA1.8.1 Pharmacovigilance System.docxDOCX
Module 1 MHRA1.8.2 Risk Management Plan.docxDOCX
Module 1 MHRA1.9 EU Information Relating to Clinical Trials.docxDOCX
Module 2 Summaries2.2 Introduction to Summary - IND.docxDOCX
Module 2 Summaries2.2 Introduction to Summary.docxDOCX
Module 2 Summaries2.3 Introduction to the Quality Overall Summary.docxDOCX
Module 2 Summaries2.3.A Appendices Non-granular.docxDOCX
Module 2 Summaries2.3.A.1 Facilities and Equipment.docxDOCX
Module 2 Summaries2.3.A.2 Adventitious Agents Safety Evaluation.docxDOCX
Module 2 Summaries2.3.A.3 Novel Excipients.docxDOCX
Module 2 Summaries2.3.P Drug Product Non-granular.docxDOCX
Module 2 Summaries2.3.P.1 Description and Composition of the Drug Product.docxDOCX
Module 2 Summaries2.3.P.2 Pharmaceutical Development.docxDOCX
Module 2 Summaries2.3.P.3 Manufacture.docxDOCX
Module 2 Summaries2.3.P.4 Control of Excipients.docxDOCX
Module 2 Summaries2.3.P.5 Control of Drug Product.docxDOCX
Module 2 Summaries2.3.P.6 Reference Standards or Materials.docxDOCX
Module 2 Summaries2.3.P.7 Container Closure System.docxDOCX
Module 2 Summaries2.3.P.8 Stability.docxDOCX
Module 2 Summaries2.3.R Regional Information.docxDOCX
Module 2 Summaries2.3.S Drug Substance Non-granular.docxDOCX
Module 2 Summaries2.3.S.1 General Information.docxDOCX
Module 2 Summaries2.3.S.2 Manufacture.docxDOCX
Module 2 Summaries2.3.S.3 Characterization.docxDOCX
Module 2 Summaries2.3.S.4 Control of Drug Substance.docxDOCX
Module 2 Summaries2.3.S.5 Reference Standards or Materials.docxDOCX
Module 2 Summaries2.3.S.6 Container Closure System.docxDOCX
Module 2 Summaries2.3.S.7 Stability.docxDOCX
Module 2 Summaries2.4 Nonclinical Overview.docxDOCX
Module 2 Summaries2.5 Clinical Overview.docxDOCX
Module 2 Summaries2.6.1 Introduction.docxDOCX
Module 2 Summaries2.6.2 Pharmacology Written Summary.docxDOCX
Module 2 Summaries2.6.3 Pharmacology Tabulated Summary.docxDOCX
Module 2 Summaries2.6.4 Pharmacokinetics Written Summary.docxDOCX
Module 2 Summaries2.6.5 Pharmacokinetics Tabulated Summary.docxDOCX
Module 2 Summaries2.6.6 Toxicology Written Summary.docxDOCX
Module 2 Summaries2.6.7 Toxicology Tabulated Summary.docxDOCX
Module 2 Summaries2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods.docxDOCX
Module 2 Summaries2.7.2 Summary of Clinical Pharmacology Studies.docxDOCX
Module 2 Summaries2.7.3 Summary of Clinical Efficacy.docxDOCX
Module 2 Summaries2.7.4 Summary of Clinical Safety.docxDOCX
Module 2 Summaries2.7.5 References.docxDOCX
Module 2 Summaries2.7.6 Synopses of Individial Studies.docxDOCX
Module 3 Quality (Granular)3.2.P.1.1 Description and Composition of the Drug Product-Description of the Dosage Form Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.1.2 Description and Composition of the Drug Product-Composition Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.1.3 Description and Composition of the Drug Product-Container Closure System Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.2.1.1 Components of the Drug Product-Drug Substance Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.2.1.2 Components of the Drug Product-Excipients Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.2.2.1 Drug Product-Formulation Development Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.2.2.2 Drug Product-Overages Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.2.2.3 Drug Product-Physiochemical and Biological Properties Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.3.3.1 Description of Manufacturing Process and Process Controls-Flow Diagram Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.3.3.2 Description of Manufacturing Process and Process Controls-Process Description Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.3.3.3 Description of Manufacturing Process and Process Controls-In Process Controls Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.4.1.1 Specifications-Compendial Excipients Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.4.1.2 Specifications-Noncompendial Excipients Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.5.4.1 Batch Analyses-Batch Information and Analytical Results Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.5.4.2 Batch Analyses-Drug Substance-Drug Product Batch Correlation Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.7.1.1 Container Closure System-Primary Packaging-Component Specification Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.7.1.2 Container Closure System-Primary Packaging-Components Drawing Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.7.1.3 Container Closure System-Primary Packaging-Analytical Procedures Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.8.1.1 Stability Summary and Conclusion-Shelf Life Period and Labeled Storage Condition Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.8.1.2 Stability Summary and Conclusion-Design of Stability Studies Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.8.1.3 Stability Summary and Conclusion-Batches Tested and Packaging Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.8.1.4 Stability Summary and Conclusion-Stability Data Discussion Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.8.1.5 Stability Summary and Conclusion-Statistical Analyses Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.8.3.1 Stability Data-Results of Stability Data Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.8.3.2 Stability Data-Analytical Procedures Granular.docxDOCX
Module 3 Quality (Granular)3.2.P.8.3.3 Stability Data-Validation of the Analytical Procedures Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.2.2.1 Description of Manufacturing Process and Process Controls-Flow Diagram Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.2.2.2 Description of Manufacturing Process and Process Controls-Manufacture Process Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.2.2.3 Description of Manufacturing Process and Process Controls-Inprocess Controls Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.2.3.1 Control of Materials-Starting Materials Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.2.3.2 Control of Materials-Starting Materials-Specifications Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.2.3.3 Control of Materials-Starting Materials-Analytical Procedures Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.2.3.4 Control of Materials-List of Reagents, Solvents and Auxilary Materials Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.2.3.5 Control of Materials-List of Reagents, Solvents and Auxilary Materials-Spec Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.2.3.6 Control of Materials-Reagents, Solvents and Auxilary Materials-Analytical Procedures Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.2.4.1 Control of Critical Steps and Intermediates-Critical Steps and Intermediates Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.2.4.2 Control of Critical Steps and Intermediates-Specifications Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.2.4.3 Control of Critical Steps and Intermediates-Analytical Procedures Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.3.2.1 Impurities List Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.3.2.2 Impurities-Structural Characterization of the Impurities Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.7.1.1 Stability Summary and Conclusions-Retest Period and Storage Conditions Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.7.1.2 Stability Summary and Conclusions-Design of Stability Studies Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.7.1.3 Stability Summary and Conclusions-Batches Tested and Packaging Granular Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.7.1.4 Stability Summary and Conclusions-Discussion of Stability Data Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.7.1.5 Stability Summary and Conclusions-Statistical Analyses Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.7.1.6 Stability Summary and Conclusions-Forced Degradation Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.7.3.1 Stability Data-Results Under Established Storage and Stress Conditions Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.7.3.2 Stability Data-Analytical Procedures Granular.docxDOCX
Module 3 Quality (Granular)3.2.S.7.3.3 Stability Data-Validation of the Analytical Procedures Granular.docxDOCX
Module 3 Quality (Non-granular)3.2.A.1 Facilities and Equipment.docxDOCX
Module 3 Quality (Non-granular)3.2.A.2 Adventitious Agents Safety Evaluation.docxDOCX
Module 3 Quality (Non-granular)3.2.A.3 Excipients.docxDOCX
Module 3 Quality (Non-granular)3.2.P.1 Description and Composition of the Drug Product Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.P.2 Pharmaceutical Development Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.P.2.1 Components of the Drug Product non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.P.2.2 Drug Product Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.P.2.3 Manufacturing Process Development.docxDOCX
Module 3 Quality (Non-granular)3.2.P.2.4 Container Closure System.docxDOCX
Module 3 Quality (Non-granular)3.2.P.2.5 Microbiological Attributes.docxDOCX
Module 3 Quality (Non-granular)3.2.P.2.6 Compatibility.docxDOCX
Module 3 Quality (Non-granular)3.2.P.3.1 Manufacturers.docxDOCX
Module 3 Quality (Non-granular)3.2.P.3.2 Batch Formula.docxDOCX
Module 3 Quality (Non-granular)3.2.P.3.3 Description of Manufacturing Process and Process Controls Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.P.3.4 Controls of Critical Steps and Intermediates.docxDOCX
Module 3 Quality (Non-granular)3.2.P.3.5 Process Validation and-or Evaluation.docxDOCX
Module 3 Quality (Non-granular)3.2.P.4.1 Specifications Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.P.4.2 Analytical Procedures-Test Method.docxDOCX
Module 3 Quality (Non-granular)3.2.P.4.2 Analytical Procedures.docxDOCX
Module 3 Quality (Non-granular)3.2.P.4.3 Validation of Analytical Procedures.docxDOCX
Module 3 Quality (Non-granular)3.2.P.4.4 Justification of Specifications.docxDOCX
Module 3 Quality (Non-granular)3.2.P.4.5 Excipients of Human or Animal Origin.docxDOCX
Module 3 Quality (Non-granular)3.2.P.4.6 Novel Excipients.docxDOCX
Module 3 Quality (Non-granular)3.2.P.5.1 Specifications.docxDOCX
Module 3 Quality (Non-granular)3.2.P.5.2 Analytical Procedures-Test Method.docxDOCX
Module 3 Quality (Non-granular)3.2.P.5.3 Validation of Analytical Procedures-Test Method.docxDOCX
Module 3 Quality (Non-granular)3.2.P.5.4 Batch Analyses Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.P.5.5 Characterization of Impurities.docxDOCX
Module 3 Quality (Non-granular)3.2.P.5.6 Justification of Specifications.docxDOCX
Module 3 Quality (Non-granular)3.2.P.6 Reference Standards or Materials.docxDOCX
Module 3 Quality (Non-granular)3.2.P.7 Container Closure System [name, dosage form].docxDOCX
Module 3 Quality (Non-granular)3.2.P.7.1 Container Closure System Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.P.8.1 Stability Summary and Conclusion Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.P.8.2 Postapproval Stability Protocol and Stability Commitment.docxDOCX
Module 3 Quality (Non-granular)3.2.P.8.3 Stability Data Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.R Regional Information_Placeholder.docxDOCX
Module 3 Quality (Non-granular)3.2.R.2 Methods Validation Package.docxDOCX
Module 3 Quality (Non-granular)3.2.S.1 General Information [name, manufacturer].docxDOCX
Module 3 Quality (Non-granular)3.2.S.1.1 Nomenclature.docxDOCX
Module 3 Quality (Non-granular)3.2.S.1.2 Structure.docxDOCX
Module 3 Quality (Non-granular)3.2.S.1.3 General Properties.docxDOCX
Module 3 Quality (Non-granular)3.2.S.2.1 Manufacturers.docxDOCX
Module 3 Quality (Non-granular)3.2.S.2.2 Description of Manufacturing Process and Process Controls Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.S.2.3 Control of Materials Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.S.2.4 Control of Critical Steps and Intermediates Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.S.2.5 Process Validation and-or Evaluation.docxDOCX
Module 3 Quality (Non-granular)3.2.S.2.6 Manufacturing Process Development.docxDOCX
Module 3 Quality (Non-granular)3.2.S.3.1 Elucidation of Structure and Other Characteristics.docxDOCX
Module 3 Quality (Non-granular)3.2.S.3.2 Impurities Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.S.4.1 Specification.docxDOCX
Module 3 Quality (Non-granular)3.2.S.4.2 Analytical Procedures-Test Method.docxDOCX
Module 3 Quality (Non-granular)3.2.S.4.3 Validation of Analytical Procedures-Test Method.docxDOCX
Module 3 Quality (Non-granular)3.2.S.4.4 Batch Analyses.docxDOCX
Module 3 Quality (Non-granular)3.2.S.4.5 Justification of Specification.docxDOCX
Module 3 Quality (Non-granular)3.2.S.5 Reference Standards or Materials.docxDOCX
Module 3 Quality (Non-granular)3.2.S.6 Container Closure System.docxDOCX
Module 3 Quality (Non-granular)3.2.S.7.1 Stability Summary and Conclusions Non-granular.docxDOCX
Module 3 Quality (Non-granular)3.2.S.7.2 Post-approval Stability Protocol and Stability Commitment.docxDOCX
Module 3 Quality (Non-granular)3.2.S.7.3 Stability Data Non-granular.docxDOCX
Module 4 Safety4.3 Literature References_Placeholder.docxDOCX
Module 4 SafetyIn Vitro Pharmacology Study Report.docxDOCX
Module 4 SafetyIn Vivo Pharmacology Study Report.docxDOCX
Module 4 SafetyPharmacokinetic Study Report.docxDOCX
Module 4 SafetyToxicology Protocol.docxDOCX
Module 4 SafetyToxicology Study Report.docxDOCX
Module 5 Efficacy16.1.1 Protocol and Amendments.docxDOCX
Module 5 Efficacy16.1.10 Inter-Laboratory Standardization Methods and Quality Assurance.docxDOCX
Module 5 Efficacy16.1.11 Publications Based on the Study.docxDOCX
Module 5 Efficacy16.1.12 Publications Referenced in the Study.docxDOCX
Module 5 Efficacy16.1.2 Sample CRF.docxDOCX
Module 5 Efficacy16.1.3 IEC and IRB and Consent Form Listings.docxDOCX
Module 5 Efficacy16.1.4 Description of Investigators and Sites.docxDOCX
Module 5 Efficacy16.1.5 Investigator Signatures.docxDOCX
Module 5 Efficacy16.1.6 Listing of Patients from Specified Batches.docxDOCX
Module 5 Efficacy16.1.7 Randomization Scheme.docxDOCX
Module 5 Efficacy16.1.8 Audit Certificate.docxDOCX
Module 5 Efficacy16.1.9 Statistical Methods and Interim Analysis Plans.docxDOCX
Module 5 Efficacy16.2.1 Discontinued Patients.docxDOCX
Module 5 Efficacy16.2.2 Protocol Deviations.docxDOCX
Module 5 Efficacy16.2.3 Patients Excluded from Efficacy Analysis.docxDOCX
Module 5 Efficacy16.2.4 Demographic Data.docxDOCX
Module 5 Efficacy16.2.5 Compliance and Drug Concentration Data.docxDOCX
Module 5 Efficacy16.2.6 Individual Efficacy Response Data Phase II-III.docxDOCX
Module 5 Efficacy16.2.6 Individual Pharmacokinetics Response Data Phase I.docxDOCX
Module 5 Efficacy16.2.7 Adverse Event Listings.docxDOCX
Module 5 Efficacy16.2.8 Individual Laboratory Measurements.docxDOCX
Module 5 Efficacy16.3.1 CRFs for Deaths, SAEs, and Withdrawals.docxDOCX
Module 5 Efficacy16.3.2 Other CRFs.docxDOCX
Module 5 Efficacy5.2 Tabular Listing of All Clinical Studies.docxDOCX
Module 5 Efficacy5.3.6 Reports of Post-Marketing Experience.docxDOCX
Module 5 Efficacy5.4 Literature References_Placeholder.docxDOCX
Module 5 EfficacyAbbrev-16.1.1 Protocol and Amendments.docxDOCX
Module 5 EfficacyAbbrev-16.1.2 Sample CRF.docxDOCX
Module 5 EfficacyAbbrev-16.2.7 Adverse Event Listings.docxDOCX
Module 5 EfficacyAbbrev-16.3.1 CRFs for Deaths, SAEs, and Withdrawals.docxDOCX
Module 5 EfficacyAbbrev-Clinical Study Report_granular body.docxDOCX
Module 5 EfficacyAbbrev-Synopsis.docxDOCX
Module 5 EfficacyAmendment Summary of Changes_Complex Option.docxDOCX
Module 5 EfficacyAmendment Summary of Changes_Simple Option.docxDOCX
Module 5 EfficacyClinical Study Report_granular body Phase I.docxDOCX
Module 5 EfficacyClinical Study Report_granular body Phase II-III.docxDOCX
Module 5 EfficacyCSR Template (Transcelerate).docxDOCX
Module 5 EfficacyICF Template.docxDOCX
Module 5 EfficacyIntegrated Summary of Efficacy.docxDOCX
Module 5 EfficacyIntegrated Summary of Safety.docxDOCX
Module 5 EfficacyPADER template.docxDOCX
Module 5 EfficacyPBRER.docxDOCX
Module 5 EfficacyPeriodic Safety Update Report (PSUR).docxDOCX
Module 5 EfficacyPharm Manual Template_Acumen.docxDOCX
Module 5 EfficacyProtocol - Clinical Study Phase I.docxDOCX
Module 5 EfficacyProtocol - Clinical Study Phase II-III.docxDOCX
Module 5 EfficacyProtocol - Clinical Study Synopsis.docxDOCX
Module 5 EfficacyProtocol - CPT template (Transcelerate).docxDOCX
Module 5 EfficacyProtocol - General Template.docxDOCX
Module 5 EfficacyProtocol - ICH M11 Template.docxDOCX
Module 5 EfficacySAP ISE.docxDOCX
Module 5 EfficacySAP ISS.docxDOCX
Module 5 EfficacySAP Phase I.docxDOCX
Module 5 EfficacySAP Phase II-III.docxDOCX
Module 5 EfficacySAP Template (Transcelerate).docxDOCX
Module 5 EfficacySynopsis Phase I.docxDOCX
Module 5 EfficacySynopsis Phase II-III.docxDOCX
Module 5 EfficacySynoptic CSR Template.docxDOCX
Samples2.4 Nonclinical Overview_SAMPLE.pdfPDF
SamplesAcumen Smart Doc Solution Sample Template (generic).docxDOCX
No templates match your search.

Template availability and contents are subject to change. Contact Acumen for current licensing details.